European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual ...
Monday, PTC Therapeutics Inc PTCT announced that the European Commission (EC) has decided not to adopt the CHMP’s negative opinion on the annual renewal of the conditional marketing authorization of Translarna (ataluren) and has returned the opinion to the …